izpis_h1_title_alt

Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor
Zakošek, Maja (Author), Prpar Mihevc, Sonja (Author), Štrbenc, Malan (Author), Košak, Urban (Author), German Ilić, Ilija (Author), Trontelj, Jurij (Author), Žakelj, Simon (Author), Gobec, Stanislav (Author), Pavlin, Darja (Author), Majdič, Gregor (Author)

.pdfPDF - Presentation file, Download (1,34 MB)
MD5: 2A7E6FFD649C1E4BB4A045BC8C9556C4
Description: Open access
URLURL - Source URL, Visit https://www.nature.com/articles/s41598-021-97404-2 This link opens in a new window

Abstract
Canine cognitive dysfunction (CCD) is common in aged dogs and has many similarities with Alzheimer’s disease. Unfortunately, like Alzheimer’s disease, CCD cannot be cured. In the present study, we treated dogs with CCD with our newly developed and characterized butyrylcholinesterase inhibitor (BChEi). Seventeen dogs were randomized into two groups (treated with BChEi and untreated) and followed for 6 months at regular check-ups. The dogs’ cognitive status was determined by a Canine Dementia Scale (CADES) questionnaire and two cognitive tests. In dogs with moderate cognitive impairment, treatment caused significant improvement in the clinical rating of cognitive abilities and the performance-based tests of cognitive functioning when compared to the untreated group (p < 0.001). Dogs treated with BChEi showed markedly improved cognitive function with enhanced quality of life. No side effects were observed in the treated dogs with moderate cognitive impairment. According to the results of this preliminary study, there is an indication that novel BChEi may be a promising drug for the treatment of CCD in dogs and may be an interesting candidate for the treatment of Alzheimer's disease in humans. However, further clinical studies are needed to confirm this.

Language:English
Keywords:Alzheimer’s disease, butyrylcholinesterase, butyrylcholinesterase inhibitor, canine cognitive dysfunction, canine dementia scale, dogs
Work type:Article (dk_c)
Tipology:1.01 - Original Scientific Article
Organization:VF - Veterinary Faculty
FFA - Faculty of Pharmacy
Year:2021
Submitted for review:15.12.2020
Article acceptance date:17.08.2021
Article publication date:13.09.2021
Number of pages:10 str.
Numbering:Vol. 11, art. 18098
UDC:636.7.09:616.892
ISSN on article:2045-2322
DOI:10.1038/s41598-021-97404-2 This link opens in a new window
COBISS.SI-ID:77000195 This link opens in a new window
Views:82
Downloads:21
Metadata:XML RDF-CHPDL DC-XML DC-RDF
 
Average score:(0 votes)
Your score:Voting is allowed only to logged in users.
:
Share:AddThis
AddThis uses cookies that require your consent. Edit consent...

Record is a part of a journal

Title:Scientific reports
Shortened title:Sci. rep.
Publisher:Nature Publishing Group
ISSN:2045-2322
COBISS.SI-ID:18727432 This link opens in a new window

Document is financed by a project

Funder:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije (ARRS)
Project no.:P4-0053
Name:Endokrini, imunski in encimski odzivi pri zdravih in bolnih živalih

Funder:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije (ARRS)
Project no.:P1-0208
Name:Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin

Funder:EC - European Commission
Name:European Regional Development Fund
Acronym:Sonja Perpar Mihevc

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:13.09.2021

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Comments

Leave comment

You have to log in to leave a comment.

Comments (0)
0 - 0 / 0
 
There are no comments!

Back